Bkm120

Manufactured by Cayman Chemical

Sourced in United States

BKM120 is a pan-PI3K inhibitor that is active against all four class I PI3K isoforms (α, β, δ, and γ). It is a potent and selective inhibitor of PI3K signaling.

Automatically generated - may contain errors

Lab products found in correlation

Bez235, by Abcam (1 mentions) Etoposide, by Fresenius (1 mentions) Cisplatin, by Fresenius (1 mentions) Byl719, by Cayman Chemical (1 mentions) Azd8186, by Cayman Chemical (1 mentions) Bortezomib, by Chemietek (1 mentions) Trametinib, by Chemietek (1 mentions) Staurosporine, by MedChemExpress (1 mentions) Verapamil, by Merck Group (1 mentions) Hydroxychloroquine, by Merck Group (1 mentions) Tariquidar, by Selleck Chemicals (1 mentions) Decitabine, by Selleck Chemicals (1 mentions) Copanlisib, by Selleck Chemicals (1 mentions) Panobinostat, by Cayman Chemical (1 mentions) Dactinomycin, by Merck Group (1 mentions) Larotrectinib, by MedChemExpress (1 mentions) Venetoclax, by Chemietek (1 mentions) Afatinib, by Selleck Chemicals (1 mentions) Vincristine, by Selleck Chemicals (1 mentions) Ceritinib, by Selleck Chemicals (1 mentions)

3 protocols using bkm120

Evaluating Cytotoxic Agents in Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Etoposide and cisplatin were purchased from Fresenius Kabi. BKM120 was obtained from Cayman Chemical. BEZ235 was obtained from BioVision.

Lai Z.Y., Yeo H.Y., Chen Y.T., Chang K.M., Chen T.C., Chuang Y.J, & Chang S.J. (2017). PI3K inhibitor enhances the cytotoxic response to etoposide and cisplatin in a newly established neuroendocrine cervical carcinoma cell line. Oncotarget, 8(28), 45323-45334.

+ Open protocol

+ Expand

Prostate Cancer Cell Line Maintenance and PI3K Inhibition

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Prostate cancer cell LNCaP, C4-2, 22RV1, DU145 and PC-3 lines were maintained in a humidified atmosphere of 5% CO₂, RPMI1640 media supplemented with 10% fetal bovine serum (FBS) and antibiotics. LNCaP/shPIK3CB#3 cell subline was established by stable transfection with a pU6+2-p110βshRNA vector as reported previously (13 (link)). C4-2B and its MDV3100-resistant subline cells (C4-2B/MDV-R) were obtained from Dr Allen Gao at UC Davis (29 (link)). TGX221 and its analogs were synthesized in house as described previously (28 ) and the aqueous solubility assay was conducted as reported (30 (link)). PI3K inhibitors including BKM120 (catalog #11587), BYL719 (catalog #16986), AZD8186 (catalog #17384), AZD6482 (catalog #15250), GSK2636771 (catalog #17380) and Akt inhibitor VIII (AKT-i8, catalog #14870) were purchased from Cayman Chemicals (Ann Arbor, MI). Antibodies for p110α (clone C73F8), p110β (clone C33D4), p110γ (clone D55D5), VPS34 (clone D4E2), Cyclin D1 (clone 92G2), CDK6 (clone DCS83), p27^kip1 (catalog #2552), pan-Akt (clone C67E7), phospho-Akt S473 (clone D9E) and T308 (clone 244F9) were obtained from Cell Signaling (Danvers, MA). Antibody for β-Actin (clone AC-15) was purchased from GeneTex Inc (Irvine, CA). Secondary antibodies for mouse and rabbit IgG as well as chemiluminescent reagent kit were purchased from Santa Cruz Biotech (Santa Cruz, CA).

He C., Duan S., Dong L., Wang Y., Hu Q., Liu C., Forrest M.L., Holzbeierlein J.M., Han S, & Li B. (2017). Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells. The Prostate, 77(11), 1187-1198.

+ Open protocol

+ Expand

Diverse Compound Sourcing for Research

Check if the same lab product or an alternative is used in the 5 most similar protocols

Vincristine (VCR, #S2141), afatinib (#S1011), tariquidar (#S8028), lapatinib (#S2111), ceritinib (#S7083), copanlisib (#S2802), and decitabine (#S1200) were purchased from Selleckchem (Houston, TX, USA). Verapamil (#V4629), dactinomycin (#A4262), and hydroxychloroquine (#C6628) were purchased from Sigma–Aldrich (Merck KGaA, Darmstadt, Germany). BKM120 (#11587) and panobinostat (#13280) were purchased from Cayman Chemicals (Ann Arbor, MI, USA). Dasatinib (#D‐3307), everolimus (#E‐4040), and olaparib (#O‐9201) were purchased from LC Laboratories (Woburn, MA, USA). Staurosporine (STS, #HY‐15141) and larotrectinib (#HY‐12866) were purchased from Medchem Express (Monmouth Junction, NJ, USA). Bortezomib (#CT‐BZ001), trametinib (#CT‐GSK112), and venetoclax (#CT‐A199‐2) were purchased from ChemieTek (Indianapolis, IN, USA). The ERBB4 blocking antibody (#MA513016) was purchased from Invitrogen (Thermo Fisher Scientific Inc.).

Rösch L., Herter S., Najafi S., Ridinger J., Peterziel H., Cinatl J., Jones D.T., Michaelis M., Witt O, & Oehme I. (2022). ERBB and P‐glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P‐glycoprotein. Molecular Oncology, 17(1), 37-58.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!